Effects of Brazilian green propolis on proteinuria and renal function in patients with chronic kidney disease: a randomized, double-blind, placebo-controlled trial

Author(s)

Duarte Silveira, Marcelo Augusto ^[1] ; Teles, Flavio ^[2] ; Berretta, Andressa A. ^[3] ; Sanches, Talita R. ^[1] ; Rodrigues, Camila Eleuterio ^[1] ; Seguro, Antonio Carlos ^[1] ; Andrade, Lucia ^[1]

Affiliation

^[1] Univ Sao Paulo, Sch Med, Div Nephrol, Av Dr Arnaldo 455, 3 Andar, Sala 3310, BR-01246903 Sao Paulo, SP - Brazil

^[2] Univ Fed Alagoas, Sch Med, Maceio - Brazil

^[3] Apis Flora Ind & Comercial Ltda, Lab Res Dev & Innovat, Ribeirao Preto - Brazil

• Document type: Journal article
• Source: BMC Nephrology; v. 20, APR 25 2019.
• Web of Science Citations: 1

Abstract

BackgroundChronic kidney disease (CKD) is a public health problem worldwide, and proteinuria is a well-established marker of disease progression in CKD patients. Propolis, a natural resin produced by bees from plant materials, has anti-inflammatory, immunomodulatory, and anti-oxidant properties, as well as having been shown to have an antiproteinuric effect in experimental CKD. The aim of this study was to evaluate the impact of Brazilian green propolis extract on proteinuria reduction and the changes in the estimated glomerular filtration rate (eGFR).MethodsThis was a randomized, double-blind, placebo-controlled study including patients with CKD caused by diabetes or of another etiology, 18-90years of age, with an eGFR of 25-70ml/min per 1.73m(2) and proteinuria (urinary protein excretion >300mg/day) or micro- or macro-albuminuria (urinary albumin-to-creatinine ratio>30mg/g or>300mg/g, respectively). We screened 148 patients and selected 32, randomly assigning them to receive 12months of Brazilian green propolis extract at a dose of 500mg/day (n=18) or 12months of a placebo (n=14).ResultsAt the end of treatment, proteinuria was significantly lower in the propolis group than in the placebo group695mg/24h (95% CI, 483 to 999) vs. 1403mg/24h (95% CI, 1031 to 1909); P=0.004independent of variations in eGFR and blood pressure, which did not differ between the groups during follow-up. Urinary monocyte chemoattractant protein-1 was also significantly lower in the propolis group than in the placebo group58pg/mg creatinine (95% CI, 36 to 95) vs. 98pg/mg creatinine (95% CI, 62 to 155); P=0.038.ConclusionsBrazilian green propolis extract was found to be safe and well tolerated, as well as to reduce proteinuria significantly in patients with diabetic and non-diabetic CKD.Trial Registration.(ClinicalTrials.gov number NCT02766036. Registered: May 9, 2016). (AU)

• FAPESP's process: 15/11933-3 - ANTIOXIDANT AND RENOPROTECTIVE EFFECTS OF ALLOPURINOL ON RHABDOMYOLYSIS SECONDARY TO GLYCEROL, STATINS, BOTHROPS VENOM AND LEPTOSPIROSIS
• Grantee: Antonio Carlos Seguro
• Support Opportunities: Regular Research Grants